NFSG
VYNE icon

Newbridge Financial Services Group’s VYNE Therapeutics VYNE Stock Holding History

Newbridge Financial Services Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6 Hold
10
– – ﹤0.01% 1174
2025
Q4 		$6 Hold
10
– – ﹤0.01% 1174
2025
Q3 		$3 Buy
+10
New +$7 ﹤0.01% 1284

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Newbridge Financial Services Group's VYNE Position: Q1 2026 in Review

Newbridge Financial Services Group held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 10 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

Newbridge Financial Services Group first reported a position in VYNE in Q3 2025 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Newbridge Financial Services Group held 10 shares of VYNE Therapeutics worth $6 as of Q1 2026.
  • Newbridge Financial Services Group left its VYNE Therapeutics share count unchanged in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1174 holding.
  • Newbridge Financial Services Group first reported a position in VYNE Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.